ANI Pharmaceuticals - M&A Summary and Business Overview

Life ScienceCompany

ANI Pharmaceuticals M&A Summary

ANI Pharmaceuticals has acquired 15 companies, including 4 in the last 5 years. A total of 1 acquisition came from private equity firms.

ANI Pharmaceuticals’ largest acquisition to date was in 2024, when it acquired Alimera Sciences for $381M. ANI Pharmaceuticals has acquired in 6 different US states, and 4 countries. The Company’s most targeted sectors include life science (87%) and medical products (14%).

ANI Pharmaceuticals Business Overview

Where is ANI Pharmaceuticals headquartered?

ANI Pharmaceuticals is headquartered in Baudette, Minnesota.

What is ANI Pharmaceuticals’ revenue?

ANI Pharmaceuticals disclosed revenue of 487M USD for 2023 and 316M USD for 2022.

How many employees does ANI Pharmaceuticals have?

ANI Pharmaceuticals has 642 employees.

What sector is ANI Pharmaceuticals in?

ANI Pharmaceuticals is a life science company.

When was ANI Pharmaceuticals founded?

ANI Pharmaceuticals was founded in 2001.

M&A Summary

  • M&A Total Activity15
    • M&A Buy Activity15
  • Total Sectors Invested 2
  • Total Countries Invested 4
  • M&A Buy/Sell Connections 11
  • M&A Advisors 8

ANI Pharmaceuticals

ANI Pharmaceuticals, Inc.

210 Main Street West,
Baudette, Minnesota 56623
United States,
(218) 634-3500
www.anipharmaceuticals.com

ANI Pharmaceuticals is a developer, manufacturer, and marketer of top-quality prescription pharmaceuticals. In two facilities with combined manufacturing, packaging, and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder, and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. ANI Pharmaceuticals was formed in 2001 and is based in Baudette, Minnesota.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.6/yr) # 12 1 1 - - 1 15
vol $114M $53M $164M $381M $711M
Sell (0.0/yr) # - - - - - - 0
  15

Most Recent M&A

Company Date Value Type
Alimera Sciences, Inc. 2024-06-24 381M USD Merger
Alpharetta, Georgia · www.alimerasciences.com
Novitium Pharma 2021-03-09 164M USD Add-on Acquisition
East Windsor, New Jersey · www.novitiumpharma.com
Amerigen Pharmaceuticals - Commercial and Pipeline Generic Products 2020-01-09 53M USD Divestiture
Suzhou, China
Coeptis Pharmaceuticals, Inc. - Seven Development Stage Drug Products 2019-06-18 14M USD Divestiture
Wexford, Pennsylvania
WellSpring Pharma Services 2018-08-09 - Add-on Acquisition
Oakville, Ontario · www.wellspringcmo.com
Amneal Pharmaceuticals LLC - Generic Products and Assets 2018-04-27 - Divestiture
Bridgewater, New Jersey
Impax Laboratories, Inc. - Generic Products and Assets 2018-04-27 - Divestiture
Hayward, California
Holmdel Pharmaceuticals LP - InnoPran XL 2017-02-24 - Divestiture
Cranford, New Jersey
Cranford Pharmaceuticals - Inderal LA Assets 2016-03-11 - Divestiture
, United States
Merck - Two NDAs 2015-09-21 75M USD Divestiture
, United States
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 13 (87%) 658M (93%) - -
Medical Products 2 (13%) 53M (7%) - -
Total 15 $711M - -

By Geo

State/Country Buy Value Sell Value
United States 12 658M - -
  New Jersey 3 164M - -
  Minnesota 2 - - -
  Pennsylvania 1 14M - -
  Georgia 1 381M - -
  California 1 - - -
Canada 1 - - -
  Ontario 1 - - -
China 1 53M - -
Israel 1 - - -
Domestic 12 (80%) 658M (93%) - -
Cross-border 3 (20%) 53M (7%) - -
Total 15 $711M - -

Top M&A Advisors

Financial Deals
Oppenheimer & Co.
1
Houlihan Lokey
1
Guggenheim Securities
1
Legal Deals
Hughes Hubbard & Reed
2
Oppenheimer Wolff & Donnelly LLP
1

Deal Values

buy # Total
$100M to $1B 2 $545M
< $100M 5 $166M
TOTAL $711M
Largest Alimera Sciences, Inc.
$381M (2024-06-24)

M&A Connections

Deals
Acquired from
Investor(s)
7%
1 (7%)
Strategic(s)
73%
11 (73%)

 Subscribe to unlock this and 208,055
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.